Table 2: Demographics of patient cohorts.

No bevacizumabBevacizumabStatistical significance of differences

HistologyGBM 20GBM 19Not significant
Gliosarcoma 1
Age (years)55 ± 9.358.7 ± 10.7Not significant
Initial KPS70 (60–80)75 (65–85)Not significant
Time to first recurrence (months)9.25 ± 4.710.5 ± 4.8Not significant
Mean time to diagnosis (from 1/1/05)25.9 ± 14.136.7 ± 8.8 𝑃 < 0 . 0 1